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Abbreviations 
 
AEC alveolar epithelial cells 
ALI acute lung injury 
ARDS adult respiratory distress syndrome 
BAL(F) bronchoalveolar lavage (fluid) 
CCR2/5 CC chemokine receptor 2/5 
CCL2/5 CC chemokine ligand 2/5 
DC dendritic cells 
(d)pi (days) post infection 
DR5 death receptor 5 
Ex-Ma exudate macrophage 
FasL Fas ligand 
FP forward primer 
HPAIV highly pathogenic avian influenza virus 
HRP horse radish peroxidase 
im intramuscular 
ip intraperitoneal 
IV influenza virus 
mAb monoclonal antibody 
MACS magnetic cell separation 
mn mononuclear 
MOI multiplicity of infection 
PB-Mo peripheral blood monocyte 
PFU plaque forming units 
PR/8 A/PR/8/34 
(r)AM (resident) alveolar macrophage 
RP reverse primer 
rpm rounds per minute 
RT room temperature 
TNF-α tumor necrosis factor-alpha 
TRAIL TNF-related apoptosis-inducing ligand 
SSC side scatter 
wt wildtype 
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1. Introduction 
 
1.1 Influenza A virus  
Influenza A virus (IV) is a highly contagious RNA virus causing infection of the 
human respiratory tract. IV infections have been recognized as a major cause of 
morbidity and mortality, especially in the very young, the very old and in 
immunocompromised individuals. Each year, influenza infections result in 3 - 5 
million cases of severe illness and kill 250,000 - 500,000 people worldwide, 
hence representing a major social and economic burden (1). Apart from annual 
epidemics, three major pandemics spread around the globe in the 20th century, 
affecting primarily young and previously healthy adults. The Spanish Flu in 
1918/19 resulted in the deaths of 50 - 100 million people (2). Further pandemics 
occurred in 1957 (Asian Flu) and 1968 (Hong Kong Flu).  
Influenza A viruses contain eight independent single-stranded RNA 
segments of negative polarity packaged in the viral core and coding for 11 
proteins: hemagglutinin, neuraminidase, nucleoprotein, matrix proteins 1 and 
2, non-structural proteins 1 and 2, polymerase A, polymerase B1, 
polymerase B1-F2, and polymerase B2 (3). The core is surrounded by a lipid 
envelope derived from the plasma membrane of infected host cells during the 
process of budding from the cellular surface (Fig. 1). Influenza A viruses belong 
to the family of orthomyxoviridae and are classified according to their surface 
glycoprotein molecules hemagglutinin (HA) and neuraminidase (NA). Sixteen 
different hemagglutinin and nine neuraminidase variants are known, but only 
subtypes A/H1N1 and A/H3N2 are usually circulating in the human population. 
However, in recent years, highly pathogenic influenza viruses have evolved 
from avian H5 or H7 strains in South-East Asia by occasional point mutations in 
the viral genome (antigenic drift) and genetic reassortment between different 
influenza viruses (antigenic shift) (4). A/H5N1 strains infected humans during 
outbreaks in 1997 and 2004/5, raising pandemic concern. Highly pathogenic 
avian influenza viruses (HPAIV), in contrast to “classical” human strains, are 
characterized by an early spread from the upper to the lower respiratory tract. 
By virtue of their high replication efficiency and their ability to attach to and 
infect distal respiratory epithelial cells, HPAIV cause primary viral pneumonia 
with rapid progression to lung failure and fatal outcome (5-9). Besides direct 
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viral cytopathic effects, the contribution of host immune response factors to 
acute lung injury during IV pneumonia has been discussed (10, 11). 
 
 
Fig. 1. Structural diagram of influenza virus (modified from Kaiser, J., Science Vol. 312, page 
380). 
 
 
1.2 Host immune response to influenza A virus infection 
Influenza A virus pneumonia is characterized by an early influx of neutrophils 
followed by the recruitment of large numbers of blood-derived monocytes within 
the first days of infection. During later stages, CD8+ cytotoxic T lymphocytes 
from mediastinal lymph nodes accumulate within inflamed lungs. The 
accumulation of large numbers of monocytes within the lung parenchyma and 
alveolar spaces has been described as a hallmark of host defense during viral 
infection initiating adaptive immune responses and thereby limiting viral spread 
(9, 12-18). The process of inflammatory leukocyte recruitment towards the lungs 
in response to IV infection is initiated by the release of early proinflammatory 
cytokines such as IFN-α/ß (interferon-α/ß), TNF-α (tumor necrosis factor-α) and 
interleukin-1 (IL-1) together with a variety of chemokines like CCL2 (MCP-1, 
monocyte chemoattractant protein-1), CCL5 (RANTES, regulated upon 
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activation, normal T cell expressed and secreted), CCL3/4 (MIP-1α/β, 
macrophage inflammatory protein-1α/β), CXCL10 (IP-10, interferon-inducible 
protein-10) and CXCL8 (IL-8, interleukin 8) from infected resident alveolar 
macrophages and lung epithelial cells (16-24). Chemokines are small cytokines 
that have been shown to act as selective chemoattractants for leukocyte 
subpopulations in vitro and to elicit the accumulation of inflammatory cells in 
vivo. The chemokine superfamily can be divided into four groups (CXC, CX3C, 
CC, and C) according to the positioning of the first two closely paired and highly 
conserved cysteines of the amino acid sequence (25). Particularly the CC 
chemokines CCL2 and CCL5 are major monocyte chemoattractants acting via 
the CC chemokine receptors CCR2 and CCR5, respectively (26-29). 
Chemokine receptors belong to the family of G protein-coupled seven-
transmembrane-spanning receptors and are primarily expressed on 
hemopoietic cells, but as well on parenchymal lung cells (30). Upon ligand 
binding, a rise in intracellular calcium flux activates specific cellular pathways 
involved in chemotaxis and changes in the avidity of cellular adhesion 
molecules, thus mediating the binding to endo- and epithelial cells and the 
migration into inflamed tissues (31). However, the chemokine-receptor 
interactions involved in alveolar monocyte transmigration during IV pneumonia 
and the role of IV infected resident alveolar epithelial cells in this context remain 
unclear so far.  
 
1.3 The lung mononuclear phagocyte system 
Peripheral blood monocytes are circulating precursors of tissue macrophages 
and dendritic cells and, together with the latter, have collectively been termed 
“the mononuclear phagocyte system”. Mononuclear phagocytes are long living 
cells with broad differentiation potential entering lung tissue by two pathways: (i) 
constitutively to regenerate resident alveolar macrophage (rAM) and lung 
dendritic cell (DC) pools and (ii) inflammation-driven to initiate and support 
immune responses (32). Forming the first line of defense against invading 
pathogens, mononuclear phagocytes have been attributed a crucial role in 
pulmonary host defense (33). 
Two major circulating monocyte subsets that vary in chemokine receptor 
and adhesion molecule expression, as well as in migratory and differentiation 
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properties, have been identified. In humans, inflammatory CD14+CD16- 
monocytes express CCR2, CD64, and CD62L, whereas non-inflammatory 
CD14lowCD16+ monocytes lack CCR2. Their counterparts in mice are CX3CR1-
CCR2+GR1high and CX3CR1+CCR2-GR1low monocytes, respectively. GR1high 
monocytes are recruited to inflammatory sites, e.g. atherosclerotic lesions, 
inflamed skin or acutely inflamed peritoneum giving rise to tissue macrophages 
and DCs in inflammatory or infectious disease models and to epidermal 
Langerhans cells after skin inflammation. In contrast, GR1low monocytes 
develop into tissue macrophages under non-inflammatory conditions (34-39).  
The mononuclear phagocyte system of the murine lung is composed of 
resident interstitial and alveolar macrophages (F4/80+GR1lowCD11chighMHCIIlow) 
and pulmonary dendritic cells (F4/80+GR1highCD11chighMHCIIhigh), both derived 
from a common CD117+ bone marrow precursor (40, 41). Under steady state 
conditions, resident lung macrophages derive from the CX3CR1+CCR2-GR1low 
peripheral blood monocyte subset with a slow turnover rate of approximately 
40% per year (42). During lung inflammation and infection, CX3CR1-
CCR2+GR1high blood monocytes (F4/80+CD11c-CD11b+CD115+) are rapidly 
recruited to the alveolar compartment of the lung (14, 36, 43). These “exudate” 
macrophages (F4/80+GR1highCD11cintMHCIIlow) acquire a lung resident 
macrophage phenotype and finally replenish the alveolar macrophage pool 
during the time course of infection (42, 44)(Fig.2). 
Besides their essential host defense functions, mononuclear phagocytes 
have been proposed to contribute to an imbalanced, detrimental immune 
response during IV pneumonia (10, 45), presumably resulting in alveolar 
epithelial damage. Human influenza virus pneumonia is characterized by acute 
mononuclear alveolitis followed by massive pulmonary oedema, hemorrhage 
and extensive destruction of the respiratory epithelium with impaired blood 
oxygenation and multi-organ failure (9, 46, 47). However, the distinct molecular 
steps during macrophage-epithelial cross-talk that lead to severe damage of the 
highly sensitive gas exchange compartment during IV-induced acute lung injury 
(ALI) or its more severe form, ARDS (adult respiratory distress syndrome), 
remain elusive.  
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Fig. 2. Murine lung mononuclear phagocytes arise from a common precursor and 
express distinct surface antigens. 
 
 
1.4 ARDS and apoptosis 
ARDS (adult respiratory distress syndrome) is a severe lung disease caused by 
a variety of direct and indirect events, the most important being bacterial or viral 
pneumonia. Recent studies report an annual incidence of up to 200,000 cases 
per year in the US (48). ARDS is characterized by leukocytic infiltrates and 
diffuse inflammation of the lung parenchyma leading to alveolar edema and 
impaired gas exchange with concomitant systemic release of inflammatory 
mediators frequently resulting in multi-organ failure. Typical histological 
presentations involve diffuse alveolar damage and hyaline membrane formation 
in alveolar walls. ARDS is defined by acute onset, bilateral pulmonary infiltrates 
in the absence of left heart failure and severe hypoxemia. Displaying a mortality 
rate of 35-40% ARDS usually    requires mechanical ventilation (48, 49).  
Several authors suggest epithelial cell apoptosis to be an underlying 
mechanism of alveolar damage in murine and human models of ARDS (50-52). 
Apoptosis is a form of programmed cell death and involves a series of 
biochemical processes resulting in cytoplasmic shrinking, loss of cellular 
polarization, membrane blebbing, nuclear chromatin condensation, and 
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chromosomal DNA fragmentation (53). The process of apoptosis is controlled 
by a wide range of cellular signals, which may originate either from an intrinsic 
or an extrinsic signal, including the TNF-α- and the Fas-Fas ligand (FasL)-
mediated pathways. Both of them involve members of the TNF receptor (TNFR) 
family such as TNFR1, TNFR2, and Fas (CD95). The binding of TNF-α or FasL 
to their receptors initiates cleavage of cysteine proteases known as caspases 
via the intermediate membrane proteins TNF receptor-associated death domain 
(TRADD) and Fas-associated death domain protein (FADD) resulting in the 
formation of the death-inducing signaling complex (DISC). Both pathways lead 
to the organised degradation of cellular organelles by activated proteolytic 
caspases (54)(Fig. 3). 
Recently, a further member of the proapoptotic TNF superfamily, tumor 
necrosis factor (TNF)-related apoptosis–inducing ligand (TRAIL), has been 
attributed a role in the orchestration of innate and adaptive immune responses 
(55-57). Being expressed mainly on T cells, NK cells, and mononuclear 
phagocyte subsets, murine TRAIL exerts its proapoptotic signals in either a 
membrane-bound or a soluble form via binding to the death receptor 5 (DR5) 
(45), and displays potent antitumor activity (58-60). Moreover, an antiviral 
function in experimental murine IV infection has been suggested (57). However, 
the contribution of TRAIL to alveolar epithelial apoptosis and lung barrier 
dysfunction during lethal IV pneumonia has not been elucidated yet. 
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Fig. 3. The extrinsic apoptosis signalling pathway is induced by death ligands TNF-α, 
TRAIL, and FasL. Upon binding to death receptors, TRADD (TNFreceptor-associated death 
domain) or FADD (Fas-associated death domain) proteins are recruited to the cytosolic receptor 
domains and, together with pro-caspase 8, form the death inducing signalling complex (DISC) 
thereby initiating the caspase cleavage cascade  which finally results in apoptosis of the cell. 
 
 
In the presented thesis, the following questions have been addressed: 
1) Which chemokine-receptor interactions mediate monocyte transepithelial 
migration across IV-infected alveolar epithelial cells in vitro? 
2) By which pathways are peripheral blood monocytes recruited to the lungs 
of IV-infected mice in vivo? 
3) Do exudate macrophages contribute to alveolar epithelial cell apoptosis 
and lung edema, and if so, which are the molecular interactions 
involved? 
 
To answer these questions, an in vitro model of monocyte transmigration across 
influenza A virus infected murine primary alveolar epithelial cells was 
established. Moreover, by the use of the mouse-adapted influenza virus 
A/PR/8/34 being highly pathogenic in mice, a murine in vivo model of IV-
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induced acute lung injury was set up to evaluate the recruitment pathways of 
peripheral blood monocytes into the lung. In addition, the contribution of lung 
exudate macrophages to alveolar epithelial cell apoptosis and lung barrier 
dysfunction, and the molecular mediators involved, were analysed in this model. 
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2. Materials and Methods 
 
2.1 Mice 
BALB/c (wildtype) mice, CCR2-deficient mice (BALB/c background), CCR5-
deficient mice (B6;129P2-Ccr5tm1Kuz/J) and wildtype mice of the corresponding 
genetic background (B6129PF2/J) served as donors for alveolar epithelial cells 
and peripheral blood monocytes used for in vitro studies. For in vivo infection 
experiments, C57/BL6 wildtype and CCR2-deficient mice (C57/BL6 
background) provided by W.A. Kuziel with a body weight of 18 – 21g were used. 
Furthermore, we made use of B6.SJL-Ptprca mice expressing the CD45.1 
alloantigen (Ly5.1 PTP) on circulating leukocytes (C57/BL6 genetic 
background) for bone marrow transplantation experiments. Mice were bred 
under specific pathogen-free (SPF) conditions. All experiments were approved 
by our local government committee of Giessen. 
 
2.2 Isolation and culture of murine primary alveolar epithelial cells 
Isolation of primary alveolar epithelial cells was performed as described by Corti 
et al. (61). Mice were killed by an overdose of isoflurane and exsanguinated by 
cutting the inferior vena cava. After opening the thorax, a small incision was 
made in the left ventricle, a 26-gauge cannula was placed into the right ventricle 
and lungs were perfused with 20ml HBSS until they were visually free of blood. 
A small cut was made into the exposed trachea to insert a shortened 21-gauge 
cannula that was firmly fixed and a total volume of 1.5 ml of sterile Dispase 
followed by 500 μl of sterile 1% low-melting agarose in PBS-/- was administered 
into the lungs. After 2 min of incubation, the lungs were removed and placed 
into a culture tube containing 2ml of Dispase for 40 min. Lungs were then 
transferred into a culture dish containing DMEM/2,5%HEPES buffer/0.01% 
DNAse and the tissue was carefully dissected from the airways and large 
vessels. The cell suspension was successively filtered, resuspended in 10ml of 
DMEM supplemented with 10% FCS and antibiotics and incubated with 
biotinylated rat-anti-mouse CD16/32 and rat-anti-mouse CD45 mAbs for 30 min 
at 37°C. Cells were then washed and incubated with Streptavidin-linked 
MagneSphere® Paramagnetic Particles for 30 min at room temperature with 
gentle rocking followed by magnetic separation of contaminating leukocytes for 
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15 min. The purity of freshly isolated AEC contained in the supernatant was 
always >90%, as assessed by pro-SPC immunofluorescence staining specific 
for type II AEC as well as immunohistochemistry for cytokeratin. Viability was 
always >95%, as analysed by trypan blue dye exclusion. For cytokine and real 
time RT-PCR analysis, AEC were plated into 24-well cell culture plates at a 
density of 5 x 105 cells/well and grown to 90% confluence for 5 days in DMEM 
supplemented with 10% FCS and antibiotics, thereby acquiring a type I alveolar 
epithelial cell phenotype, as verified by loss of pro-SPC staining. For 
transmigration assays, 3 x 105 AEC were seeded onto the lower side of 
transwell filter inserts (6.4 mm diameter, 8 µm pore size) and grown for 5 days 
until they reached 100% confluence.  
2.3 Isolation of peripheral blood monocytes 
For isolation of peripheral blood monocytes (PB-Mo), mice were sacrificed by 
an overdose of isoflurane and blood was drawn via the V. cava inferior, 
transferred into sterile EDTA tubes and diluted with 3ml of PBS-/-. Whole blood 
cells were carefully layered over 3ml Lympholyte®. Cells were centrifuged at 
1400 rpm at room temperature for 35 min to separate the mononuclear fraction. 
The interphase was collected and mononuclear cells were washed twice in 
RPMI 1640 supplemented with 10% FCS and antibiotics (10 min, 1200 rpm, 
RT). Monocytes were further enriched by depleting lymphocytes and CD8-
positive NK cells by MACS negative selection using anti-mouse CD4, anti-
mouse CD8 and anti-mouse CD19 mAbs, resulting in a final purity of  >90%, as 
assessed by differential counts on Pappenheim-stained cytocentrifuge 
preparations. Viability of PB-Mo was analysed by trypan blue dye exclusion and 
was always >95%. 
 
2.4 Virus strain and in vitro infection of AEC 
Influenza A virus strain A/PR/8/34 (H1N1; PR/8) was grown in the allantoic 
cavity of embryonated hen eggs. Virus titer was determined by plaque assay on 
confluent Madin Darby canine kidney cells (see below). AEC cultured on 
transwells or 24-well plates were washed with PBS-/- and infected with 
influenza A virus at a MOI of 1 (unless otherwise indicated) in a total volume of 
100 µl PBS/BA containing 0.2% bovine serum albumin, 1mM MgCl2, 0.9mM 
CaCl2, 100U penicillin/ml and 0.1mg streptomycin/ml or with diluent alone 
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(mock-infection) for 1 h at room temperature. Subsequently, the inoculum was 
removed and cells were incubated with DMEM supplemented with 2% FCS and 
2 μg/ml trypsin (PAA) at 37°C for the indicated time periods. 
 
2.5 Monocyte transmigration assay 
For transepithelial migration assays, virus- or mock-infected AEC grown on 
transwells were incubated in 500 μl DMEM supplemented with 2% FCS and 
antibiotics added to the lower compartment of 24-well ultra low cluster plates for 
32 h. In some experiments, recombinant murine CCL2 or CCL5 were added to 
the medium of non-infected AEC. 4 x 105 PB-Mo in 100μl RPMI/10% FCS were 
then added into transwell inserts to allow their transmigration through AEC in a 
basal towards apical orientation of the epithelial monolayer for 90 min at 37°C. 
Transmigrated monocytes were collected from the lower chamber with 200μl 
aliquots of ice-cold 5 mM EDTA in PBS-/-, then centrifuged and resuspended in 
50μl RPMI and total cell numbers were counted in a hemocytometer. In 
selected experiments, neutralizing anti-CCL2 mAb (1μg/ml) was added to the 
medium of each well at 6, 12, and 20 h after infection. 
 
2.6 Cytokine quantification 
Cytokine levels in the supernatants of infected AEC or in bronchoalveolar 
lavage fluid (BALF; see below) were measured using commercially available 
colorimetric sandwich ELISA kits.  Standards were prepared by serial 1:10 
dilutions with assay diluent. Standards, samples and positive controls were 
added to the antibody-coated plate in duplicates and incubated for 2 h at RT. 
Plates were washed five times with 400µl of washing buffer with an ELISA 
autowasher. After incubation with 100µl of conjugate solution per well for 2 h 
and additional washing steps, 100µl of substrate solution was added for 30min 
and the reaction was stopped. Optical density was measured using a microplate 
reader set to 450nm. Detection limits were 2 pg/ml for CCL2 and CCL5, and 5.1 
pg/ml for TNF-α. 
 
2.7 In vivo infection and mouse treatment protocols 
2.7.1 Intratracheal infection with influenza virus PR/8 
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Mice were anesthetized with xylazine hydrochloride (2.5mg/kg im) and ketamine 
hydrochloride (50mg/kg im), and the neck fur above the trachea was shaved 
followed by desinfection of the skin. A small incision was made, and the 
underlying connective tissue was bluntly dissected to expose the trachea. A 26-
gauge Abbocath was inserted into the trachea, and mice were slowly inoculated 
with 500PFU of influenza virus PR/8 diluted in sterile PBS-/- in a total volume of 
70μl or mock-infected with PBS-/- alone. Subsequently, the catheter was 
removed, and the skin was sutured. Mice were allowed to recover from 
anesthesia and were then returned to their cages, with free access to food and 
water. In some experiments, mice were anesthetized as described above and 
azide-free function-blocking mAbs (75μg anti-CCR2 (29) in 100μl PBS-/- at d0 
and d4 pi or 150μg anti-TRAIL (N2B2) in 150μl PBS-/- at d3 and d5 or at d3, d5, 
d7, and d9) or respective isotype IgG control antibodies were injected 
intraperitoneally. For body weight and survival analysis PR/8 infected mice were 
observed and weighed every 24 h pi for 21 days. 
 
2.7.2 Bronchoalveolar lavage 
At the indicated time points, mice were sacrificed by an overdose of isoflurane 
and bronchoalveolar lavage (BAL) was performed as follows: After exposure of 
the trachea, a small incision was made to insert a shortened 21-gauge cannula 
that was firmly fixed and then connected to a 1ml syringe filled with 300µl of 
PBS-/-/5mM EDTA (pH 7.2). BAL was performed with 300µl aliquots until an 
initial BAL volume of 1.5ml was recovered. The cells were separated by 
centrifugation (10 min, 1200rpm, 4°C), and the supernatant was used for 
quantification of CCL2 and TNF-  protein or for the lung permeability assay (see 
below). Subsequently, BAL was completed with 500µl aliquots until an 
additional BAL volume of 4.5ml was recovered. BAL cells from the first and 
second BAL fraction were pooled, counted with a hemacytometer and 
differential cell counts of Pappenheim-stained cytocentrifuge preparations were 
performed using overall morphological criteria, including differences in cell size 
and shape of nuclei. For flow cytometric analysis, BAL leukocytes were fixed in 
ice-cold PBS-/-/1%PFA for 15 min, washed and resuspended in FACS buffer 
(PBS-/- supplemented with 7.4 % (v/v) EDTA and 0.5 % (v/v) FCS). 
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2.7.3 Isolation of peripheral blood leukocytes 
For isolation of peripheral blood leukocytes mice were sacrificed at the indicated 
time points and the abdominal cavity was rapidly opened to expose the vena 
cava. Blood was drawn into a 23-gauge cannula connected to a 1-ml insulin 
syringe that was filled with 200µl of NaCl-EDTA as an anticoagulant. Blood 
samples were hemolysed in a total volume of 10 ml of an ammonium chloride 
solution (pH 7.2) for 3 min and leukocytes were resuspended in RPMI/10%FCS, 
washed (10 min, 1200rpm, RT), and after a second hemolysis step fixed in ice-
cold PBS-/-/1%PFA for 15 min before resuspension in FACS buffer for further 
flow cytometric analysis. 
 
2.8 Preparation of lung homogenates 
PR/8 or mock infected mice were sacrificed at the indicated time points and 
exsanguinated by cutting the V. cava inferior. After opening the thorax, a small 
incision was made in the left ventricle, a 26-gauge cannula was placed into the 
right ventricle and lungs were perfused with 20ml HBSS until they were visually 
free of blood. 1.5ml of Dispase followed by 500μl of 1% low-melting agarose in 
PBS-/- were administered into the lungs via the trachea through a firmly fixed 
21-gauge cannula. After 2 min of incubation, the lungs were dissected out of the 
thorax and put into a culture tube containing 2ml of Dispase for 40 min at RT. 
Lungs were then transferred into a culture dish containing DMEM/2,5%HEPES 
buffer and 0.01% DNAse and the tissue was carefully dissected from the 
airways and large vessels with forceps and sheared through a 1ml pipet tip. The 
cell suspension was successively filtered through 100µm- and 40µm-filters, 
washed twice in DMEM/10%FCS and resuspended in Annexin V staining buffer 
(10 mM HEPES, 140 mM NaCl, and 2.5 mM CaCl2) or FACS buffer for flow 
cytometric analysis. 
 
2.9 Lung permeability assay 
For the determination of alveolar leakage mice received an intravenous injection 
of 1mg FITC-labelled albumin in 100μl of sterile NaCl 0.9%. 45 min later, BALF 
and blood samples were collected as described above. Blood samples were 
incubated for 3 h at RT without addition of EDTA until coagulation occurred and 
serum was recovered after centrifugation (3500rpm, 15 min, RT). FITC 
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fluorescence was measured in duplicates in undiluted BALF and serum 
samples (diluted 1:100 in PBS-/-) and compared to standard samples serially 
diluted 1:10 with PBS-/- using a fluorescence spectrometer. The lung 
permeability index is defined as the ratio of fluorescence signals of undiluted 
BALF samples to fluorescence signals of 1:100 diluted serum samples and 
given as arbitrary units (AU). 
 
2.10 Quantification of lung virus titers  
Lungs from PR/8 infected mice were dissected out of the thorax and heart and 
connective tissue were removed. Lungs were mechanically homogenized in 2ml 
PBS+/+ in glass douncers on ice, centrifuged at 4000rpm for 10 min at 4°C and 
supernatants were serially diluted (1:100 to 1:107) in PBS/BA. Virus titers were 
determined by immunohistochemistry on confluent Madin Darby canine kidney 
cells in 96-well plates in duplicates. Cells were incubated with 50μl of 
homogenate dilution for 1 h at room temperature and after removal of the 
inoculum covered with 1.5% methylcellulose media containing 2μg/ml trypsin for 
72 h. Cells were permeabilised and fixed with PBS+/+/4%PFA/1%Triton X-100, 
washed three times with 400µl of Tween buffer (0.2% Tween 20 in PBS-/-) and 
incubated with diluted primary mouse anti-IV nucleoprotein-mAb for 45 min at 
RT. After three washing steps, diluted HRP-conjugated anti-mouse IgG was 
added for 45 min. After additional washing steps, the peroxidase substrate AEC 
(3-amino-9-ethylcarbazole) was added for 10 min. Foci were counted using a 
Leica light microscope and are given as foci forming units (FFU) per lung. 
 
2.11 Flow cytometry and cell sorting 
Flow cytometric analysis was performed using a FACSCanto flow cytometer 
(BD Biosciences) equipped with a FACSDiva Software package.  
 
2.11.1 Chemokine receptor analysis on isolated PB-Mo 
Chemokine receptor analysis on isolated PB-Mo was performed as follows: 
Cells were washed and incubated for 40 min at 4°C with rat anti-mouse CCR5 
(MC68), rat anti-mouse CCR2 (MC21), both provided by M. Mack (29), or rat 
IgG isotype antibodies, all diluted to working concentrations. Unspecific 
antibody binding was inhibited by adding 10μl Fc-Block. Cells were then 
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washed twice with FACS buffer and incubated with PE-labelled goat anti-rat IgG 
for 20 min at 4°C. After two further washing steps, CCR2 and CCR5 expression 
were analysed in the PE-channel.  
 
2.11.2 Analysis of leukocyte subpopulations in BAL from PR/8 infected mice 
For flow cytometric analysis of fixed blood or BAL leukocytes from in vivo 
experiments 5x105 cells were washed in FACS buffer. Unspecific antibody 
binding was inhibited by adding 10μl Fc-Block. Cells were stained with 
biotinylated or fluorochrome-labeled primary mAbs and analysed either for 
“myeloid” cell composition (CD45.2-FITC (30F-11), GR1-PE (RB6-8C5), 
biotinylated I-A/I-E (2G9), F4/80-Alexa647 (CI:A3-1), CD11c-PE-Cy5.5 (418)) or 
for lymphocyte subpopulations (CD45.2-PerCP-Cy5.5 (30F-11), NK1.1-APC 
(PK136), CD4-FITC (RM4-4), biotinylated CD8α (53-6.7)). Antibodies were 
diluted to working concentrations and added for 20 min. After 2 washing steps 
with FACS buffer (3 min, 1200rpm, 4°C), biotinylated primary mAbs were further 
incubated with 5µl of 1:100 diluted APC-Cy7-conjugated streptavidin for 5 min 
and 5-colour flow cytometry was performed. Data from the myeloid cell analysis 
is given as dot plots and represent a three-hierarchy gating. CD45+ cells (P1, 
leukocytes) were gated according to their GR1- and F4/80-expression. 
GR1intF4/80+ cells represent alveolar mononuclear phagocytes (P2). Subgate 
analysis of P2 revealed a CD11cint (P3, exudate macrophages), and a 
CD11chigh (P4, resident AM) subpopulation, as well as a CD11chighMHCIIhigh 
subpopulation (P5) representing alveolar dendritic cells. Lymphocyte 
subpopulation analysis (NK-cells, CD4 T-cells, CD8 T-cells) was performed by 
gating on CD45-positive cells and their relative proportion was calculated 
according to their NK1.1-, CD4-, and CD8a-expression, respectively. 
 
2.11.3 Analysis of bone marrow transplantation efficiency 
For analysis of bone marrow engraftment efficiency in chimeric mice (see 
below), fixed BAL and blood cells were stained with anti-mouse CD45.2-FITC 
(30F-11) and CD45.1-PE (A20) mAbs for 20 min and the relative proportions of 
donor (CD45.2) and recipient (CD45.1) leukocytes in blood and of resident AM 
in BAL was calculated. 
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2.11.4 Quantification of alveolar type I epithelial cell apoptosis from PR/8 
infected lung homogenates 
Epithelial apoptosis in lung homogenates was analysed by quantitation of 
annexin V binding. 1x106 cells were washed in annexin V staining buffer. 
Unspecific antibody binding was inhibited by adding 10μl Fc-Block. Cells were 
stained with PE-labelled anti-mouse CD45.2 (30F-11) mAb, hamster anti-mouse 
T1α mAb and annexin V-Alexa647 conjugate, each diluted to working 
concentrations, for 20 min. After two washing steps, cells were further incubated 
with Alexa 488-labelled anti-hamster Ig secondary antibody for 20 min. CD45-
negative cells were gated and analysed for their T1α expression (FITC-channel) 
and annexin V binding (APC-channel).  
 
2.11.5 Quantification of TRAIL expression on BAL leukocytes  
Analysis of TRAIL expression on BAL leukocytes was performed as described 
above with either a combination of GR1-FITC (RB6-8C5), F4/80-Alexa647 
(CI:A3-1), and TRAIL-PE (N2B2, or rat isotype-PE IgG) anti-mouse mAbs or a 
combination of NK1.1-APC (PK136), CD4-FITC (RM4-4), biotinylated CD8α 
(53-6.7) and TRAIL-PE (N2B2, or rat isotype-PE IgG) anti-mouse mAbs 
followed by further incubation with 5µl of 1:100 diluted APC-Cy7-conjugated 
streptavidin for 5 min. TRAIL expression on mononuclear phagocytes 
(GR1intF4/80+), neutophils (GR1intF4/80+), NK-cells (SSClowNK1.1+), CD4 T cells 
(SSClowCD4+), and CD8 T cells (SSClowCD8a+) was quantified.  
 
2.11.6 DIVA-assisted high speed sorting of PB-Mo and exudate macrophages 
For cell sorting experiments, unfixed BAL cells pooled from 8 mice per 
experiment were incubated with GR1-PE-Cy7 (RB6-8C5), F4/80-Alexa488 
(BM8), and CD11c-PE (HL3) anti-mouse mAbs for 20 min. Unfixed blood 
leukocytes from the same animals or from mock-infected mice were pooled and 
stained with anti-mouse CD11b-FITC (M1/70) and CD115-PE (MCA1898) mAbs 
for 20 min. F4/80+GR1intCD11cint BAL cells (exudate macrophages) and 
SSClowCD11bhighCD115high blood cells (PB-Mo) were high-purity sorted with a 
FACSVantage SE flow cytometer equipped with a DIVA sort option, an argon-
ion laser operating at 488 nm excitation wavelength and a HeNe laser operating 
at 633 nm excitation wavelength. The BD FACSDIVA software package was 
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used for data analysis. After cell sorting, the purity of the cell preparations was 
analyzed by 1) postsort analysis of sorted cells and 2) differential cell counts of 
Pappenheim-stained sorted cells. The cell purity of sorted peripheral blood 
monocytes and exudate alveolar macrophages was always >90%. 
 
2.11.7 Quantification of DR5 expression on PR/8 infected alveolar type I 
epithelial cells from lung homogenates 
1x106 lung homogenate cells were prepared as described in chapter 2.8 and 
fixed for 15 min in PBS/1%PFA before resuspension in FACS buffer, 
permeabilized with 0.2% saponin and unspecific antibody binding was inhibited 
by adding 10μl Fc-Block. Cells were stained with PE-labelled anti-mouse 
CD45.2-PE-Cy5.5 (30F-11) mAb, hamster anti-mouse T1α mAb, mouse anti-
influenza nucleoprotein mAb (clone 1331), and rat anti-mouse DR5 (TNFR2) 
mAb or rat isotype IgG control, each diluted to working concentrations, for 20 
min. After two washing steps, cells were further incubated with Alexa 488-
labelled anti-hamster Ig, Alexa 647-labelled anti-mouse Ig, and PE-labelled anti-
rat Ig secondary antibodies for 20 min. CD45-negative/T1α-positive cells were 
gated and analysed for their nucleoprotein and DR5 expression. 
 
2.12 Generation of bone marrow chimeric mice 
Bone marrow cells were isolated under sterile conditions from the tibias and 
femurs of wildtype C57/BL6 or from CCR2-/- donor mice. The proximal and distal 
ends of donor tibias and femurs were cut with a scalpel and flushed with sterile 
RPMI/10% FCS. A bone marrow single cell suspension was prepared, filtered 
through 70 μm and 40 μm nylon meshes and cell suspensions were then 
washed in Leibovitz L15 medium prior to transplantation. Recipient wildtype 
C57/BL6 mice received 6 Gy of lethal body irradiation. A total of 1.2 x 107 
wildtype or CCR2-/- donor bone marrow cells were transplanted via intravenous 
injection into the tail vein of sedated wildtype recipient mice. For some 
experiments, wildtype and CCR2-/- bone marrow cells were mixed at a 1:1 ratio 
prior to transplantation. As controls for bone marrow engraftment, wildtype 
C57/BL6 bone marrow cells (expressing the CD45.2 alloantigen) were 
transplanted into CD45.1 alloantigen-expressing mice (n=2 during each 
transplantation experiment) and the proportion of CD45.2 positive peripheral 
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blood and BAL leukocytes was analysed by flow cytometry as described above. 
Bone marrow engraftment was 90.5 ± 2.7% after two weeks post 
transplantation. Chimeric mice were housed under SPF conditions for 14d prior 
to PR/8 infection. 
 
2.13 Preparation of lung tissue sections and TUNEL assay 
HBSS-perfused lungs were carefully lavaged with 400μl aliquots of PBS-/-/2mM 
EDTA to wash out alveolar leukocytes and thereafter slowly inflated with 1,5ml 
of a 1:1 mixture of TissueTek OCT and PBS-/-, removed en bloc and snap-
frozen in liquid nitrogen. Lung tissue cryosections were mounted on glass slides 
and dried overnight at room temperature. Apoptotic cells were stained using the 
DeadEnd® Colorimetric TUNEL system. Sections were fixed in PBS-/-/4%PFA, 
washed and permeabilized with Proteinase K solution. Fragmentated DNA was 
labeled by incorporation of biotinylated nucleotides at the 3`-OH-ends using 
deoxynucleotidyl transferase (TdT reaction mix). Thereafter, the reaction was 
stopped with 2xSSC, washed, and 100μl of Streptavidin-linked HRP were 
added on the slides. After additional washing steps the sections were 
developed with 100μl of DAB (3,3’-diaminobenzidine), washed and mounted in 
aqueous mounting medium. Slides were analysed with a Leica DM 2000 light 
microscope at the indicated magnification using a Leica digital imaging 
software. 
 
2.14 RNA isolation and real time RT-PCR 
Flow-sorted blood monocytes and exudate macrophages were lysed with RLT 
buffer containing ß-mercaptoethanol and RNA was isolated with spin columns 
using the RNeasy Micro Kit, whereas RNA from cultured alveolar epithelial cells 
was isolated by PeqGold Total RNA kit. For cDNA synthesis, 2-500ng of 
denatured template was added to a mastermix containing 5μl 5x1st strand 
buffer, 2.5μl DDT, 0.5μl Rnase inhibitor, 1μl 10mM DNTPs, 1.5μl Random 
Hexamers, 0.25μl dH2O, and 0.75μl MMLV-Reverse Transcriptase per reaction, 
incubated for 50 min on 37°C and the reaction was stopped by heating to 96°C 
for 5 min in a PE GeneAmp PCR System 2400. For analysis of quantitative 
mRNA expression PBGD was used as the reference gene. Reactions were 
performed in an ABI 7900 Sequence Detection System using SYBR-Green I as 
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fluorogenic probe in 25μl reactions containing 5μl cDNA sample, 1× Platinum 
SYBR® Green qPCR SuperMix and 45 pmol forward and reverse primers. The 
following primer sequences were used:  
 
TNF-α: FP: 5’- CAT CTT CTC AAA ATT CGA GTG ACA A-3’,  
RP: 5’-  TGG GAG TAG ACA AGG TAC AAC CC-3’;  
FasL:  FP: 5’-CCA ACC AAA GCC TTA AAG TAT CAT C-3’,  
RP: 5’- AAC CCA GTT TCG TTG ATC ACA A-3’;  
TRAIL:  FP: 5’- GAA GAC CTC AGA AAG TGG C -3’,  
RP: 5’ – GAC CAG CTC TCC ATT CCT A-3’;  
DR5:   FP: 5’- AAG TGT GTC TCC AAA ACG G-3’,  
RP: 5’ – AAT GCA CAG AGT TCG CAC T – 3’;  
PBGD:  FP: 5’ – GGT ACA AGG CTT TCA GCA TCG -3’,  
RP: 5’ – ATG TCC GGT AAC GGC GGC -3’.  
Relative expression was determined by the 2ΔΔCt method. 
 
2.15 Statistical analysis 
All data are given as mean ± SD. For analysis of statistical differences, one-
factor ANOVA with posthoc test by Dunnett or Student´s t-test were applied. 
Statistical significances between treatment groups were calculated with the 
SPSS for Windows software program. Significance was assumed when p 
values were ≤ 0.05. 
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3. Results 
 
3.1 PR/8 infection of AEC promotes monocyte transepithelial migration 
To investigate whether PR/8 infection of AEC provokes a basal-to-apical 
monocyte transepithelial migration, isolated peripheral blood monocytes were 
added to transwell filter inserts containing either PR/8 or mock-infected AEC. 
Transmigration rates were compared to monocyte migration across mock-
infected AEC driven by recombinant CCL2 or CCL5 that was added to the lower 
transwell compartment. Monocyte transmigration across PR/8 infected AEC 
monolayers was increased 10-fold compared to transmigration across mock-
infected AEC, indicating that PR/8 infection of AEC strongly induced monocyte 
recruitment across the infected epithelial cell barrier. Monocyte transmigration 
across PR/8 infected AEC even exceeded monocyte migration across mock-
infected AEC driven by exogenously added recombinant CCL2 or CCL5 (Fig. 
4).  
                      
Fig. 4. PR/8 infection of AEC promotes transepithelial migration of peripheral blood 
monocytes. Monocytes purified from peripheral blood were allowed to transmigrate either 
mock-infected AEC, PR/8 infected AEC (32 h) or mock-infected AEC in the presence of 
recombinant CCL2 or CCL5 added to the lower transwell compartment (200 ng/ml) in a basal-
to-apical direction for 90 min. Values are presented as mean ± SD from n = 5 experiments; *p < 
0.05 for comparison with mock-infected AEC.  
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3.2 Monocyte transmigration induced by epithelial PR/8 infection is 
dependent on the CCL2/CCR2  axis 
To further characterize the chemotactic factors driving in vitro monocyte 
transmigration across PR/8 infected AEC, we evaluated whether PR/8 infection 
of AEC induced the release of the major monocyte-attracting chemokines, 
CCL2 and CCL5 into the supernatant. Both CCL2 and CCL5 release was 
induced in a time- and MOI-dependent manner peaking at 32 h post-infection at 
a MOI of 1 (Fig. 5). To further evaluate the role of epithelial-derived CCL2 or 
CCL5 to drive transepithelial monocyte migration, peripheral blood monocytes 
collected from mice lacking the respective chemokine receptors (CCR2-/- or 
CCR5-/-) were compared with congenic wild-type monocytes for their 
transmigration capacity across PR/8 infected AEC. As demonstrated in Fig. 6A, 
both CCR2 and CCR5 were expressed on wild-type monocytes. Lack of the 
CCL2 receptor on monocytes collected from CCR2-/- mice resulted in a 90% 
reduced monocyte transepithelial migration. Moreover, neutralization of 
epithelial cell-derived CCL2 by addition of CCL2-neutralizing antibodies similarly 
reduced the monocyte transmigration. In contrast, CCR5-deficient monocytes 
transmigrated PR/8 infected epithelium to the same extent as wild-type 
monocytes (Fig. 6B). These data demonstrate a crucial role for the CCL2/CCR2 
axis in monocyte migration across influenza A virus infected alveolar epithelial 
cells. 
          
Fig. 5. CCL2 and CCL5 release from PR/8 infected AEC. AEC were mock-infected (white 
bars) or infected with PR/8 for the given time periods with the following MOIs: 0.1 (light grey 
bars), 0.5 (medium grey bars), 1 (dark grey bars), or 2 (black bars). Values are presented as 
mean ± SD (n = 3 for all experiments except at 32 h where n = 4); **p < 0.01 and *p < 0.05 for 
comparison with mock-infected AEC of the respective time point.  
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Fig. 6. Monocyte transmigration across PR/8 infected AEC is CCL2/CCR2 dependent. (A) 
Representative FACS histograms of CCR2 (left panel) and CCR5 (right panel) expression on 
PB-Mo (x-axis, PE-fluorescence; y-axis, total events; white histograms, PE-labeled isotype 
control; grey histograms, anti-CCR5-PE or anti-CCR2-PE). (B) Monocytes derived from CCR2-/- 
or CCR5-/- mice or from wild-type mice were allowed to transmigrate PR/8 infected AEC isolated 
from corresponding wild-type mice. Where indicated, neutralizing anti-CCL2 antibodies (1µg/ml) 
were added to the AEC medium followed by wild-type monocyte transmigration. Values are 
presented as percent monocyte transmigration calculated from each experiment (mean ± SD of 
at least 5 independent experiments); **p < 0.01. 
 
 
3.3 CCR2-deficiency selectively affects alveolar mononuclear phagocyte 
recruitment during IV pneumonia 
To evaluate the amount and composition of alveolar leukocyte infiltration in 
PR/8 infected wildtype and CCR2-/- mice, total BALF cell counts and cell 
differentials were determined at various time points post infection. No significant 
differences in total BALF cell counts were detectable between the two treatment 
groups (Fig. 7).  
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Fig. 7. Quantification of total leukocyte numbers in BALF of PR/8 infected wt (■) or CCR2-
/- (□) mice (n=3–5 mice per group, values are given as mean ± SD). 
 
 
Morphologic analysis of leukocyte composition from Pappenheim-stained BALF 
cytospin preparations of PR/8 infected wildtype or CCR2-/- mice revealed that 
peak alveolar neutrophil accumulation was delayed in CCR2-deficient mice but 
did not significantly differ from peak values reached in wildtype mice (CCR2-/- 
mice: 73.3 ± 8.0% on day 7 pi; wildtype mice: 63.6 ± 17.8% on day 3 pi), being 
in line with previous reports (21). Lymphocyte recruitment was virtually identical 
in both treatment groups as was the reduction of the resident alveolar 
macrophage proportion in BALF that reflects the pronounced alveolar 
accumulation of leukocytes in both wildtype and CCR2-deficient mice during the 
time course of infection. However, alveolar mononuclear phagocyte recruitment 
was found to be strongly reduced in CCR2-deficient mice, most prominent at 
day 8 post infection (34.3 ± 7.4% vs. 7.6 ± 6.7%; Fig. 8).  
Correspondingly, exudate mononuclear phagocyte numbers were 
significantly decreased in PR/8 infected wildtype mice pretreated 
intraperitoneally with an anti-CCR2 antibody by day 8 post infection, as 
compared to mice treated with isotype control (Fig. 9). 
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Fig. 8. Quantification of BAL leukocyte subpopulations from Pappenheim-stained 
cytocentrifuge preparations of PR/8 infected wt (■) or CCR2-/- (□) mice (values are given as 
mean ± SD of n=3–5 mice per group; *** p < 0.005; AM, alveolar macrophages; mn, 
mononuclear). 
 
                                  
Fig. 9. Quantification of BALF exudate mononuclear phagocytes from PR/8 infected wt 
mice treated with IgG isotype or anti-CCR2 mAb. Values are calculated from differential 
counts of BAL leukocytes and are given as mean ± SD of n=5 mice per group; * p < 0.05. 
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To further dissect the alveolar mononuclear phagocyte subset composition, 
BALF cells gained from PR/8 infected mice of the various treatment groups 
were subjected to flow cytometric analysis for surface marker expression at day 
8 post infection. Analysis of CD45+ BALF cells (leukocytes, P1; Fig. 10, first 
column) for GR1 and F4/80 expression revealed three distinct cell populations: 
Gr1highF4/80- neutrophils, GR1-F4/80- lymphocytes, and GR1intF4/80+ 
mononuclear phagocytes (P2; Fig. 10, second column), which were composed 
of a CD11cint (P3, henceforth termed “exudate macrophages”) and a CD11chigh 
(P4) subpopulation, representing resident alveolar macrophages, according to 
previous reports (40, 41). Exudate macrophages (P3) accumulated to a much 
lesser extent in CCR2-/- mice or in mice pretreated with anti-CCR2 antibodies as 
compared to wildtype mice or isotype-treated mice, respectively (Fig. 10, third 
column). Alveolar mononuclear phagocytes (P2) contained a low proportion of 
dendritic cells (CD11c+MHCIIhigh, P5; Fig. 10, fourth column).  
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Fig. 10. Flow cytometric analysis of alveolar mononuclear phagocyte subpopulations in 
PR/8 infected wt versus CCR2-/- mice or in wt mice treated with IgG isotype or anti-CCR2 
mAb was performed by three-hierarchy gating on d8 pi. CD45+ cells (P1) were gated according 
to their GR1- and F4/80-expression. GR1intF4/80+ cells represent alveolar mononuclear 
phagocytes (P2). Subgate analysis of P2 revealed a CD11cint (P3, exudate macrophages), and 
a CD11chigh (P4, resident AM) subpopulation, as well as a CD11chighMHCIIhigh subpopulation 
(P5) representing alveolar dendritic cells; ist, isotype control. 
 
 
Flow cytometric quantification of alveolar dendritic cell accumulation or 
lymphocyte subset recruitment was performed in wildtype and CCR2-deficient 
mice on various time points post PR/8 infection. Alveolar dendritic cell 
recruitment was delayed in PR/8 infected CCR2-/- mice but reached peak values 
comparable to wildtype mice by day 8 post infection (Fig. 11, left panel). Flow 
cytometric analysis of alveolar lymphocyte subsets revealed no striking 
differences in the recruitment of NK cells, CD4+ T cells or CD8+ T cells between 
wildtype and CCR2-deficient mice at the given time points (Fig. 11).  
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Fig. 11. Flow cytometric quantification of CD11chighMHCIIhigh dendritic cells (left panel) 
and lymphocyte subpopulations from BAL leukocytes of PR/8 infected wt (■) versus 
CCR2-/- (□) mice (using the gating characteristics described in Fig. 7 for dendritic cells). For 
analysis of lymphocyte subpopulations, CD45+ cells were subgated on NK cells (SSClowNK1.1+), 
CD4 T cells (SSClowCD4+), and CD8 T cells (SSClowCD8+). Data is given as percent of CD45+ 
cells; n=3-5 mice per experiment; *** p < 0.005; SSC, side scatter. 
 
 
As shown in Fig. 12, quantification of the primary CCR2 ligand, CCL2, in BAL 
fluid revealed a pronounced alveolar CCL2 release upon PR/8 infection in both 
wildtype and CCR2-deficient mice, with CCL2 secretion being even > 10-fold 
higher in CCR2-/- mice at day 5 post infection, an effect which has been 
described previously (62).  
Altogether, corresponding to the in vitro findings, the presented data 
demonstrate that accumulation of GR1intF4/80+CD11cintMHCIIlow exudate 
macrophages in the alveolar air space during PR/8 pneumonia was severely 
impaired in CCR2-deficient mice or wildtype animals treated with function 
blocking anti-CCR2 antibodies, demonstrating a key role of the CCL2/CCR2-
axis during IV-induced lung macrophage recruitment in vivo.  
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Fig. 12. Quantification of CCL2 levels in BALF from PR/8 infected wt and CCR2-/- mice. 
Mice were inoculated with PR/8 and BAL was performed at the indicated time point post 
infection prior to CCL2 protein quantification by ELISA (values depict means ± SD of n=3-5 mice 
per time point). 
 
 
 
3.4 Genetic deletion of CCR2 reduces mortality, morbidity, and alveolar 
barrier dysfunction during PR/8 infection 
To investigate whether exudate macrophage recruitment to the lungs of IV-
infected mice might affect the outcome of IV pneumonia, wildtype and CCR2-/- 
mice were intratracheally inoculated with PR/8 and survival and body weight 
were determined during 21 days post infection. As shown in Figure 13B, only 
17.3% of CCR2-deficient mice succumbed to PR/8 infection as compared to 
78.4% of infected wildtype mice (p < 0.005 on days 14 to 21 pi). Likewise, body 
weight loss was significantly less in CCR2-/- mice on days 8, 9, and 11 post 
infection (Fig. 13A). 
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Fig. 13. CCR2 deficiency is associated with reduced body weight loss (A) and increased 
survival (B). Sex- and age-matched wt (♦, n=23) or CCR2-/- (■, n=23) mice were PR/8 infected 
at day 0 and body weight and survival were determined until day 21 pi.  
 
 
To evaluate whether the observed differences in morbidity and mortality during 
PR/8 infection were associated with increased severity of lung injury in wildtype 
mice as compared to CCR2-/- mice, alveolar barrier function was assessed 
during a time course of 21 days post PR/8 infection in the two treatment groups. 
Indeed, alveolar leakage was significantly reduced in CCR2-deficient mice on 
day 7 post infection (1.25 ± 0.39 vs. 0.54 ± 0.37 AU, Fig. 14A). 
Correspondingly, treatment of infected wildtype mice with an anti-CCR2 mAb 
was associated with reduced alveolar leakage, as compared to isotype-treated 
mice on day 7 post infection (Fig. 14B), suggesting a key role of CCR2-
dependently recruited mononuclear phagocytes in IV-induced lung barrier 
breakdown. 
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Fig. 14. Alveolar leakage in PR/8 infected wt (■) and CCR2-/- (□) mice (A) and in wildtype 
mice pretreated with IgG isotype or anti-CCR2 mAb (B). BALF and serum samples were 
taken from PR/8 infected mice at the indicated time point post infection 45 min after FITC-
albumin injection and the lung permeability assay was performed. Values are given in means ± 
SD of n=3-5 animals per group; *p<0.05. 
 
 
During IV pneumonia, alveolar epithelial injury may be caused by direct 
cytopathic effects of IV replicating primarily in epithelial cells. Therefore, we 
evaluated whether the observed differences in lung barrier damage between 
wildtype and CCR2-/- mice were linked to different viral replication efficiencies 
in the lung tissue of the two mouse strains. Analyses of viral replication in lung 
homogenates from PR/8 infected wildtype compared to CCR2-/- mice revealed 
no significant differences in peak viral titers at days 2, 3 and 5 post infection and 
even slightly elevated virus titers in CCR2-/- mice during later stages of infection 
(1.05 ± 1.33 x 103 versus 6.20 ± 3.90 x 103 FFU/lung on day 11 pi, Fig. 15).  
These results indicate that enhanced alveolar injury in wildtype mice 
during PR/8 pneumonia is not due to higher viral replication rates than in CCR2-
/- mice and rather suggest that mononuclear phagocytes recruited to inflamed 
tissues in a CCR2-dependent manner may directly cause alveolar damage 
during IV pneumonia. 
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Fig. 15. Lung virus titers of wt (♦) and CCR2-/- (■) mice in the time course of PR/8 
infection. PR/8 infected mice were sacrificed at the indicated time points post infection and 
virus titers were determined from lung homogenate supernatants. Values are given as foci 
forming units (FFU) per lung and are means ± SD from n=3-5 mice per group; * p < 0.05. 
 
 
3.5 CCR2 expression on circulating leukocytes but not on lung resident 
cells is associated with alveolar barrier dysfunction during PR/8 infection 
To distinguish whether CCR2 expressed on resident lung cells, such as resident 
alveolar macrophages or alveolar epithelial cells, or CCR2 present on 
circulating leukocytes accounted for the increased IV-induced alveolar leakage 
in wildtype vs. CCR2-/- mice, we made use of a  bone marrow chimeric mouse 
model. We established three different transplantation groups: (i) wildtype mice 
which were transplanted 100% wildtype bone marrow cells, (ii) wildtype mice 
which were transplanted a mixture of wildtype and CCR2-/- bone marrow cells 
(50% wildtype/50% CCR2-/-), and (iii) wildtype mice which were transplanted 
100% CCR2-/- bone marrow cells. Bone marrow transplantation efficiency was 
analysed in CD45.1 alloantigen-expressing mice which were transplanted 
wildtype bone marrow cells (expressing the CD45.2 alloantigen, n=2 during 
each transplantation experiment) by calculating the proportion of CD45.2 
positive donor peripheral blood leukocytes and of CD45.1 positive recipient 
resident alveolar macrophages by flow cytometry. Bone marrow engraftment 
was 90.5 ± 2.7% after two weeks post transplantation, whereas 92.2 ± 5.5% of 
resident alveolar macrophages exhibited a recipient phenotype (Fig. 16). 
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Fig.16. Analysis of transplantation efficiency in CD45.1 alloantigen expressing mice 14 
days after transplantation of CD45.2 positive bone marrow. CD45.1 mice were lethally 
eradiated and transplanted 1.2 x 107 CD45.2 bone marrow cells by intravenous injection. Bone 
marrow engraftment of recipient CD45.1 mice was analysed 14d later in peripheral blood 
leukocytes by flow cytometry. Note, that resident alveolar macrophages were of recipient origin 
14d post transplantation. Left panel: peripheral blood leukocytes (PBL), right panel: resident 
alveolar macrophages gained by BAL. 
 
 
Exudate macrophage accumulation on day 8 post PR/8 infection in transplanted 
mice was dependent on the proportion of peripheral blood monocytes with intact 
CCR2 expression, with mice transplanted wildtype bone marrow recruiting 0.85 
± 0.27 x 106, mice transplanted mixed bone marrow recruiting 0.57 ± 0.29 x 106, 
and mice transplanted CCR2-/- bone marrow recruiting a total of 0.24 ± 0.09 x 
106 exudate macrophages into the alveolar compartment (Fig. 17A). Fig. 17B 
shows a representative flow cytometry dot plot analysis of BAL leukocytes from 
the three treatment groups performed as described in chapter 3.3. 
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Fig. 17. Exudate macrophage recruitment is dependent on circulating monocyte-
expressed CCR2. (A) Exudate macrophage numbers of the three different groups of PR/8 
infected chimeric mice calculated from BALF leukocyte cell numbers and differential counts of 
Pappenheim-stained cytocentrifuge preparations. Values are given as means ± SD from n=4-8 
mice per transplantation group; *** p < 0.005. (B) Flow cytometric analysis (representative 
experiment) of BALF cells from PR/8 infected chimeric mice. Note that P3 (exudate 
macrophages), P4 (resident alveolar macrophages), and P5 (alveolar dendritic cells) are 
subgates of P2 (mononuclear phagocytes). 
 
 
Analysis of alveolar leakage at day 7 post infection revealed a significant 
reduction in mice transplanted mixed or 100% CCR2-/- bone marrow compared 
to mice transplanted 100% wildtype bone marrow. Of note, about 50% reduction 
of alveolar macrophage accumulation was sufficient to attenuate alveolar 
leakage to levels obtained in mice transplanted CCR2-/- bone marrow only (Fig. 
18). These results clearly demonstrate that CCR2 expressed on circulating 
blood monocytes mediates their extravasation into the alveolar compartment of 
the lung, thereby contributing to alveolar barrier dysfunction during IV 
pneumonia. 
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Fig. 18. Alveolar barrier dysfunction is associated with CCR2 expression on circulating 
monocytes during PR/8 infection. Alveolar leakage from PR/8 infected chimeric mice of the 
three different transplantation groups was determined by the lung permeability assay at d7 pi. 
All values are given as means ± SD from n=4-8 mice per transplantation group; *** p < 0.005. 
 
 
3.6 CCR2-dependent alveolar exudate macrophage accumulation is 
associated with increased alveolar epithelial cell apoptosis 
Given that the CCR2-dependent accumulation of exudate macrophages in IV 
pneumonia contributed to the loss of alveolar barrier integrity, we hypothesized 
that this recruited mononuclear cell population might promote barrier 
dysfunction by inducing alveolar epithelial apoptosis. Therefore, cryosections 
from lavaged lungs of mock- or PR/8-infected wildtype or CCR2-deficient mice 
were subjected to TUNEL assay. As shown in Figure 19A, the number of 
apoptotic alveolar cells was strikingly less in PR/8-infected CCR2-/- mice as 
compared to wildtype mice, and virtually undetectable in mock-infected wildtype 
or CCR2-deficient mice.  
For apoptosis quantification of alveolar epithelial type I cells representing 
the major component of the alveolar surface, lung homogenates of the 
respective treatment groups were subjected to flow cytometry and CD45- cells 
were analysed for annexin V binding and expression of the alveolar epithelial 
cell type I marker T1α.  Representative dot plots in Fig 19B (left panel) 
demonstrate a significantly larger proportion of type I alveolar epithelial cells to 
undergo apoptosis in lung homogenates of PR/8-infected wildtype mice (49.4 ± 
14.3%) than in PR/8-infected CCR2-deficient mice (28.0 ± 8.7%). Notably, 
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CCR2-/- mice still exhibited a 28% alveolar epithelial apoptosis rate. Apoptosis 
of type I alveolar epithelial cells was undetectable in homogenates of mock-
infected wildtype and CCR2-/- mice (Fig. 19C). 
 
      
 
Fig. 19. (A) Alveolar epithelial cell apoptosis is reduced in PR/8 infected CCR2-/- mice as 
compared to wt mice, and virtually undetectable in mock infected mice. Note that nuclei of 
apoptotic cells appear in brown; arrow, apoptotic intraalveolar leukocyte; arrowhead, apoptotic 
alveolar epithelial cell; magnification x 400. (B) Flow cytometric quantification of apoptotic 
alveolar epithelial cells. Representative dot plots show expression of the alveolar epithelial cell 
type I marker T1α and annexin V staining of viable (propidium-iodide negative) CD45-negative 
cells. Note that apoptotic cells are mainly alveolar epithelial cells type I (left panel). (C) 
Quantification of flow cytometric data of n=3-6 mice per group; bar graphs represent the 
annexin V positive proportion of CD45-negative cells and are given as means ± SD; * p < 0.05. 
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3.7 Alveolar exudate macrophages upregulate mRNA levels of the 
proapoptotic TNF-related apoptosis-inducing ligand (TRAIL) as compared 
to peripheral blood monocytes 
To analyse mRNA levels of potential proapoptotic factors in alveolar exudate 
macrophages and their blood precursors, peripheral blood monocytes from 
mock-infected or PR/8-infected wildtype mice as well as alveolar exudate 
macrophages from PR/8-infected wildtype mice were flow-sorted on day 8 post 
infection according to scatter and surface marker characteristics as shown in 
Fig. 20A and analysed for TNF-α, TRAIL, and FasL transcripts using 
quantitative RT-PCR. TNF-α mRNA transcripts were found to be significantly 
increased to the same level in both peripheral blood monocytes and alveolar 
exudate macrophages from PR/8-infected mice as compared to blood 
monocytes from mock-infected mice (Fig. 20B, left panel). However, TNF-α 
protein levels in BAL fluid did not significantly differ between PR/8-infected 
wildtype and CCR2-deficient mice (Fig. 20C), suggesting that exudate 
macrophages recruited to the alveolar space in wildtype but less in CCR2-/- 
mice were not the primary source of TNF-α. No significant upregulation of FasL 
mRNA could be detected in the analysed cell populations (Fig. 20B, middle 
panel). In contrast, TRAIL mRNA was selectively upregulated 4-fold in exudate 
macrophages as compared to their peripheral blood precursors from either 
mock- or PR/8-infected mice (Fig. 20B, right panel).  
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Fig. 20. Relative mRNA expression of the proapoptotic factors TNF-α, TRAIL and FasL in 
flow-sorted peripheral blood monocytes and alveolar exudate macrophages. (A) BALF 
exudate alveolar macrophages from PR/8 infected mice were high purity flow-sorted according 
to their surface expression of F4/80, GR1 and CD11c (F4/80+GR1intCD11cint, P3, left panels). 
Peripheral blood monocytes from the same (PR/8 infected) animals or from mock-infected mice 
were flow-sorted according to their scatter characteristics (SSClow) and their CD11b and CD115-
expression (CD11b+CD115+, P3, right panels); SSC, side scatter; FSC, forward scatter. (B) 
Relative mRNA expression of the proapoptotic factors TNF-α, TRAIL and FasL of flow-sorted 
peripheral blood monocytes. Values are given as mean ± SD from n=3 independent 
experiments including pooled BALF or blood cells from n=8 mice each; * p < 0.05; ns, not 
significant. (C) Quantification of TNF-α protein levels in BALF of PR/8 infected wt (■) and CCR2-
/- (□) mice. 
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3.8 TRAIL expression in the alveolar space is largely restricted to alveolar 
exudate macrophages during PR/8 infection 
To evaluate TRAIL protein expression on the surface of alveolar mononuclear 
phagocytes, BALF cells from mock- or PR/8-infected wildtype or CCR2-/- mice 
were analysed by flow cytometry for F4/80 and TRAIL co-expression by day 8 
post infection. TRAIL was exclusively found on F4/80+ BALF cells from PR/8-
infected wildtype but not CCR2-deficient mice, indicating that only CCR2-
dependently recruited exudate macrophages, but not resident alveolar 
macrophages expressed TRAIL (Fig. 21A). The proportion of TRAIL+ alveolar 
macrophages raised to ~14% in PR/8-infected wildtype mice on day 8 post 
infection and was always below 1.5% in CCR2-deficient mice in the time course 
of infection (Fig. 21B). As opposed to previous reports (57, 63), in our model, 
TRAIL was only expressed on a small proportion of alveolar NK cells and 
absent on alveolar CD4+ and CD8+ T cells as well as on alveolar neutrophils 
from both wildtype and CCR2-/- mice at the indicated time points (Fig. 22).  
 
       
 
Fig. 21. TRAIL is expressed on the cell surface of alveolar exudate macrophages. (A) BAL 
leukocytes of mock or PR/8 infected wt or CCR2-/- mice were stained with GR1-FITC, F4/80-
Alexa647 and TRAIL-PE or isotype-PE mAbs, respectively, for flow cytometric analysis of 
TRAIL expression on day 8 pi.  GR1intF4/80+ cells were gated and analysed for their TRAIL 
surface expression. (B) Quantitative analysis of the proportion of TRAIL+ from F4/80+ BALF cells 
gained from PR/8-infected wt (■) or CCR2-/- (□) mice. Values are given as mean ± SD from n=3-
4 mice per group; *** p < 0.005. 
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Fig. 22. Flow cytometric analysis of TRAIL expression on alveolar recruited cell 
populations. BAL leukocytes of PR/8-infected wt or CCR2-/- mice were subjected to flow 
cytometry and gated for NK-cells (SSClowNK1.1+), neutrophils (GR1highF4/80-), CD8 T cells 
(SSClowCD8+), and CD4 T cells (SSClowCD4+) and analysed for TRAIL expression. 
 
 
3.9 Anti-TRAIL treatment attenuates alveolar epithelial apoptosis as well 
as lung leakage and enhances survival after PR/8 infection 
To evaluate the contribution of exudate macrophage TRAIL to alveolar epithelial 
apoptosis, TUNEL assay was performed on cryosections of lavaged lungs from 
PR/8 infected wildtype mice treated with IgG isotype or anti-TRAIL mAb, 
respectively. As shown in Fig. 23A, alveolar cell apoptosis was pronounced in 
isotype-treated, but significantly decreased in anti-TRAIL-treated mice on day 7 
post PR/8 infection. In addition, anti-TRAIL treatment significantly reduced 
annexin V binding of alveolar epithelial cells type I in PR/8 infected lung 
homogenates as compared to isotype-treated controls, as demonstrated in a 
representative flow cytometry dot plot (Fig. 23B) and in the quantitative analysis 
in Fig. 23C. Of note, alveolar epithelial cell apoptosis could not be completely 
abrogated by anti-TRAIL treatment, suggesting an additional role for TRAIL-
independent epithelial apoptosis in PR/8 infected lungs possibly due to 
cytopathic effects by epithelial IV-replication itself (Fig. 23C).  
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Fig. 23. Anti-TRAIL treatment attenuates alveolar epithelial cell apoptosis upon PR/8 
infection. (A) PR/8-infected wt mice were treated with IgG isotype or anti-TRAIL mAb as 
described in Materials and Methods and TUNEL assay was performed from lung cryosections at 
day 7 pi (arrow, apoptotic intraalveolar leukocyte; arrowhead, apoptotic alveolar epithelial cell; 
magnification x 400). (B) Flow cytometric analysis of apoptotic type I alveolar epithelial cells 
from PR/8-infected isotype- or anti-TRAIL-treated mice was performed by annexin V binding. 
(C) Quantification of flow cytometric data was performed from n=3-6 mice per group; bar graphs 
represent the annexin V positive proportion of CD45-negative cells and are given as means ± 
SD; *** p < 0.005 
 
 
 
Interestingly, TRAIL receptor (DR5) mRNA transcripts were found to be present 
in cultured primary murine alveolar epithelial cells and were upregulated upon 
PR/8 infection in a dose-dependent manner in vitro (Fig. 24A). Flow cytometric 
analysis of lung homogenates from PR/8 infected or non-infected wildtype mice 
revealed that 21.5 ± 1.3% of alveolar type I cells (CD45-T1α+) were PR/8 
infected at d5 pi, as shown by IV nucleoprotein (NP) expression in a 
representative FACS dot plot in Fig. 24B. NP-positive alveolar type I epithelial 
cells showed an upregulated DR5 protein expression as compared to NP-
negative type I cells (Fig. 24C).  
                                  
***
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Fig. 24. TRAIL receptor (DR5) is expressed on isolated alveolar epithelial cells and 
upregulated upon PR/8 infection in vitro and in vivo . (A) Cultured primary AEC were either 
mock- or PR/8-infected with the indicated MOI for 8 h, and quantitative RT-PCR was performed. 
Bar graphs depict DR5 mRNA expression as fold induction of mock-infected alveolar epithelial 
cells. Values are given as means ± SD of n=3 independent experiments. (B) Lung homogenates 
from PR/8 infected (d5 pi) or non-infected (d0) wildtype mice were subjected to flow cytometry 
and CD45-T1α+ alveolar type I cells were gated and analysed for influenza nucleoprotein (NP) 
and DR5 expression. (C) Representative FACS histograms of DR5 expression on the surface of 
CD45-T1α+ alveolar type I cells in non-infected wildtype mice (d0) and in PR/8-infected wildtype 
mice at d7 pi (light grey, isotype control; medium grey, NP-negative type I cells; dark grey, NP-
positive type I cells); ist, isotype. 
 
Analysis of alveolar barrier function in anti-TRAIL treated, PR/8-infected 
wildtype mice revealed a significant decrease in alveolar leakage in comparison 
to isotype-treated control mice on day 7 post infection (Fig. 25A). Reduction of 
alveolar leakage in anti-TRAIL treated mice was associated with significantly 
increased survival of IV infection as compared to isotype-treated controls (Fig. 
25B). These data clearly demonstrate a crucial role of TRAIL expressed by 
alveolar exudate macrophages in the development of alveolar barrier 
dysfunction as a major determinant of mortality during influenza virus 
pneumonia in mice. 
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Fig. 25. Anti-TRAIL treatment attenuates alveolar leakage and enhances survival upon 
PR/8 infection. (A) PR/8-infected wt mice were treated with IgG isotype or anti-TRAIL mAb and 
sacrificed to perform the lung permeability assay on day 7 pi. Values are given as means ± SD 
from n=5 mice per group; * p = 0.05. (B) Survival of PR/8-infected wt mice treated with igG 
isotype or anti-TRAIL mAb was analysed until day 21 pi (p < 0.05).  
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4. Discussion 
 
Mononuclear phagocytes of the lung, in particular newly recruited “exudate“ 
macrophages, have been attributed a crucial role in host defense towards IV 
infection. Moreover, macrophages were considered to contribute to an 
imbalanced, detrimental immune response during IV pneumonia presumably 
resulting in alveolar epithelial damage and acute lung injury. In the present 
thesis, alveolar recruitment pathways of peripheral blood 
monocytes/macrophages upon influenza virus infection were analysed in vitro 
and in vivo, demonstrating a crucial role of the CCL2/CCR2 axis. Moreover, the 
hypothesis that exudate macrophages, recruited to the lung in a CCL2/CCR2-
dependent manner, might contribute to lung barrier dysfunction during lethal 
influenza virus infection was tested. In fact, alveolar barrier function, severely 
disturbed in IV-infected wildtype mice, was found to be significantly less 
affected in CCR2-deficient mice exhibiting defective exudate macrophage 
recruitment. Consequently, CCR2-deficiency was associated with drastically 
decreased mortality during experimental IV pneumonia. Moreover, the 
pronounced lung leakage observed in wildtype mice correlated with an 
increased alveolar epithelial cell apoptosis rate found to be induced by the TNF-
related apoptosis-inducing ligand (TRAIL) that is predominantly expressed in 
exudate lung macrophages. Finally, treatment of IV infected wildtype mice with 
an anti-TRAIL mAb not only attenuated alveolar leakage but significantly 
reduced mortality from IV pneumonia. Taken together, these results 
demonstrate that macrophage recruitment to IV-infected lungs in mice exerts 
detrimental effects on lung parenchymal cells of the highly sensitive gas 
exchange compartment, severely affecting alveolar barrier function via TRAIL- 
induced epithelial apoptosis (Fig. 26). 
 
4.1 CCR2/CCL2 dependency of monocyte/macrophage lung recruitment in 
vitro and in vivo 
The presented data demonstrate that influenza A virus infection of primary 
alveolar epithelial cells elicits a basal-to-apical monocyte transepithelial 
migration across infected epithelium in vitro. Although virus-infected alveolar 
epithelial cells displayed a pronounced release of both chemoattractants CCL2 
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and CCL5, monocyte transmigration across PR/8 infected epithelium was only 
dependent on monocyte CCR2 but not CCR5 receptor expression. Previous 
reports demonstrated an impaired monocyte recruitment into the lungs of CCR2 
knockout but not CCL5 or CCR5 knockout mice upon influenza A virus infection 
in vivo, without addressing the contribution of distinct alveolar cell types to the 
mononuclear phagocyte trafficking in response to influenza A virus infection (14, 
64, 65). The current data add to the aforementioned studies and provide 
evidence for an active role of virus-infected alveolar epithelial cells to elicit a 
basal-to-apical monocyte transepithelial migration in a CCL2 but not CCL5 
dependent fashion, as demonstrated by the use of CCL2-neutralizing 
antibodies. Interestingly, the CCL2/CCR2 axis was found to be crucial for 
monocyte transmigration, as opposed to the role of CCR5. Thus, these findings 
demonstrate a major role of the CCL2/CCR2 axis in monocyte-epithelial 
interactions leading to monocyte recruitment across the influenza virus infected 
alveolar epithelial barrier. The fact that transmigration of CCR5-deficient 
monocytes across virus-infected epithelium was not affected when compared to 
wildtype monocytes strongly argues against a major contribution of CCL5 to 
monocyte transepithelial migration in our system, which is additionally 
supported by the findings that CCL2 release from influenza-infected epithelial 
cells exceeded the CCL5 release by a factor of 3, and by the observation that 
monocyte recruitment across mock-infected epithelium was much weaker in 
response to recombinant CCL5 as compared to CCL2. 
Consistent with the presented in vitro data, exudate macrophage 
accumulation upon PR/8 infection in vivo was strictly dependent on monocyte-
expressed CCR2. Although it has been reported that CCR2 might also bind 
CCL8, CCL16 and CCL26 (66-68), alveolar macrophage recruitment was most 
likely initiated via an interaction with its primary ligand CCL2, being released 
into the alveolar compartment to large amounts. Surprisingly, CCL2 secretion 
revealed to be > 10-fold higher in CCR2-/- mice than in wildtype mice, an effect 
which has been described previously, presumably resulting from reduced CCL2 
consumption by invading macrophages (62). 
The CCL2/CCR2 axis is known to play a crucial role in host defense 
against pathogens by mediating the recruitment of GR1+ peripheral blood 
monocytes to sites of infection, thereby expanding the resident mononuclear 
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phagocyte pool. CCR2-/- and CCL2-/- mice were found to be extremely 
susceptible to acute toxoplasmosis and were unable to survive typically 
nonlethal doses of a nonvirulent strain of T. gondii (38). In a model of hepatic 
CMV infection, CCL2- and CCR2-deficient mice in comparison to wildtype mice 
exhibited increased viral titers, widespread virus-induced liver pathology and 
succumbed to infection (69). Moreover, CCL2 overexpressing mice displayed 
an improved pneumococcal clearance and survival compared to wildtype mice 
associated with substantially increased lung mononuclear phagocyte subset 
accumulations upon pneumococcal challenge (33). In striking contrast, in the 
presented model, CCR2-deficiency was found to be associated with only a 
slight (yet significant) delay in PR/8 clearance confirming observations reported 
previously by Dawson et al. (14) who suggest delayed adaptive immune 
responses being the underlying mechanism. However, we were not able to 
detect significant differences in the alveolar accumulation of CD4+ or CD8+ T 
lymphocytes, despite the observed delay in dendritic cell recruitment, known as 
the major antigen-presenting cell population. These results are supported by the 
findings of Osterholzer and colleagues, demonstrating that immature DC 
recruitment to the lungs of mice in response to particulate antigen was only 
partially dependent on CCR2 (70). Of note, in the present thesis, persistent IV 
replication in CCR2-/- mice seemingly had no effect on alveolar epithelial 
integrity, emphazising the predominant role of host as opposed to pathogen 
factors in IV-induced pathology.  
 
4.2 Contribution of CCR2-dependently recruited exudate macrophages to 
IV-induced acute lung injury 
Influenza virus pneumonia is characterized by rapid development of acute lung 
injury with poor outcome. One of the hallmarks of acute lung injury is an 
incremental alveolar barrier dysfunction followed by accumulation of protein-rich 
edema fluid in the alveolar compartment (9, 71, 72), and acute respiratory 
distress syndrome (ARDS). ARDS is a clinical syndrome characterized by 
damage to the alveolo–capillary interface, usually secondary to an intense 
inflammatory response of the host lung to bacterial or viral infections. Several 
studies have demonstrated that respiratory infections lead to impairment of the 
alveolar epi- and endothelium, resulting in increased thickness of alveolo–
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capillary membranes and decreased number of ventilated alveoli with reduced 
peripheral oxygenation (73, 74). Both viral pathogenicity factors and imbalanced 
host immune responses have been attributed a role in IV-induced ARDS (75, 
76). It is believed that ARDS is a clinical syndrome secondary to an intense, 
usually neutrophil-predominant host inflammatory response (49). After 
stimulation by proinflammatory cytokines, activated neutrophils release free 
radicals, inflammatory mediators, and proteases, which lead to lung damage 
(73). However, in the presented model, it is clearly demonstrated that alveolar 
recruited neutrophils did not account for the severe alveolar damage observed 
in PR/8 infected mice, as neutrophils were recruited to the lungs of CCR2-
deficient mice to a large extent, and even slightly exceeded alveolar neutrophil 
accumulation in wildtype mice. Thus, we assumed that the reduced lung 
leakage and mortality observed in CCR2-deficient mice during IV-infection 
might be attributed to abrogated pulmonary macrophage accumulation. In fact, 
as demonstrated by the use of chimeric mice, loss of alveolar barrier function 
was solely dependent on CCR2 expression on circulating monocytes, indicating 
that mononuclear phagocyte traffic was critically involved and that CCR2-
positive resident lung cell populations, such as alveolar epithelial cells and 
resident alveolar macrophages, did not contribute to increased lung 
permeability in the presented model. Interestingly, a reduction of lung 
macrophage recruitment by 50% resulted in an approximately 5-fold decrease 
in alveolar leakage, suggesting that partial inhibition of macrophage recruitment 
during IV pneumonia may strongly attenuate lung injury while presumably 
maintaining critical macrophage host defense functions.  
 
4.3 Role of exudate macrophage TNF-related apoptosis-inducing ligand 
(TRAIL) in acute lung injury upon IV pneumonia 
Alveolar epithelial apoptosis has been described as a common feature of acute 
lung injury caused by direct or indirect factors, such as pneumonia, aspiration, 
sepsis or trauma (50-52, 77). Apoptosis is a regulated form of cell death that is 
mediated by membrane death receptors (extrinsic pathway) and direct 
mitochondrial injury (intrinsic pathway). Apoptosis has been described to occur 
in the lungs of patients with acute lung injury by activation of the epithelial 
membrane Fas death receptor by soluble Fas ligand (sFasL), released from 
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invading leukocytes and accumulating in biologically active form at the onset of 
lung injury (78-80). However, in our model of IV-induced acute lung injury, FasL 
transcripts were not significantly regulated in the macrophage subsets 
analysed. In contrast, the proapoptotic molecule TRAIL not expressed in 
peripheral blood monocytes was found to be strongly upregulated in exudate 
macrophages recruited into the alveolar space in IV-infected wildtype mice, 
whereas TRAIL was undetectable in alveolar mononuclear phagocytes of IV-
infected CCR2-/- mice. TRAIL induction in alveolar exudate macrophages may 
be due to the recruitment process into the lung itself or to inflammatory 
mediators present within the IV-infected alveolar compartment. Previous reports 
identified type I interferons as potent inducers of TRAIL in monocytes and 
dendritic cells (59, 81). Indeed, in the presented study, interferon-α was 
alveolarly released upon PR/8 infection in wildtype mice, yet peaking early by 
day 2 post infection (219 ± 78pg/ml). TRAIL, acting as a membrane-bound or 
soluble form, has been known to induce apoptosis in various tumour cells, but 
not in non-neoplastic cells (58, 59). Recently, TRAIL expressed on lymphocyte 
subpopulations, dendritic cells and monocyte-derived macrophages has been 
associated with anti-viral host responses during IV-infection (56, 57, 82), 
underlining the importance of death pathways in anti-viral immunity. In contrast, 
Wurzer et al. found TRAIL-induced programmed cell death pathways to be 
crucial for IV propagation (83). In mice, TRAIL exclusively acts via the 
membrane death receptor 5 (DR5) expressed on the target cell. Interestingly, 
DR5 was upregulated in primary murine alveolar epithelial cells in vitro and in 
vivo upon PR/8 infection in a dose-dependent manner, suggesting that a 
preceding epithelial IV-infection might facilitate TRAIL-induced apoptosis as a 
potential host mechanism to limit viral spread. However, DR5 mRNA expression 
was also detectable in uninfected epithelial cells, suggesting that exudate 
macrophage TRAIL may have the potential to attack non-infected epithelial cells 
when released in large amounts.  
Altogether, the present data demonstrate a key role of exudate 
macrophage TRAIL in alveolar epithelial cell apoptosis promoting alveolar 
barrier dysfunction during IV lung infection. Notably, inhibition of TRAIL activity 
largely protected mice from lethal influenza virus pneumonia. Targeting the 
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TRAIL-DR5 pathway might therefore be a suitable tool to restore lung epithelial 
function in patients suffering from severe IV-pneumonia. 
 
 
 
 
 
Fig. 26. Proposed model of macrophage-epithelial interactions during IV-induced acute 
lung injury: Peripheral blood monocytes are recruited in a CCL2/CCR2-dependent manner 
across PR/8-infected alveolar epithelial cells. Upon transepithelial migration into the alveolar air 
space, peripheral blood monocytes acquire an exudate macrophage phenotype and upregulate 
TRAIL, thereby inducing type I alveolar epithelial cell apoptosis. This process is supported by a 
PR/8-dependent upregulation of the TRAIL receptor DR5 on the alveolar epithelium. Alveolar 
epithelial cell apoptosis is followed by destruction of the thin alvoelo-capillary gas exchange 
barrier, accompanied by alveolar edema formation as a determinant of morbidity and mortality 
in IV-induced ALI. 
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5. Summary 
 
Influenza A virus pneumonia is characterized by rapid progression to lung 
failure and high mortality. During early stages of infection significant amounts of 
leukocytes accumulate within the lung parenchyma including peripheral blood 
monocytes/macrophages, neutrophils and lymphocytes. Among these, 
macrophages have been attributed a crucial role in the host defense towards 
influenza virus (IV). In contrast, the precise transepithelial recruitment pathways 
of peripheral blood monocytes into the alveolar air space and the potential 
contribution of alveolarly accumulating (“exudate”) macrophages to alveolar 
epithelial damage and lung barrier dysfunction during IV pneumonia has not yet 
been adequately addressed. Therefore, the present thesis investigated the 
chemokine-receptor involvement during IV-induced transepithelial monocyte 
migration in vitro and in vivo. Infection of primary murine alveolar epithelial cells 
with the mouse-adapted influenza A virus strain PR/8 markedly induced the 
release of the monocyte chemoattractants CCL2 and CCL5 followed by a strong 
monocyte transepithelial migration. This monocyte migratory response was 
strictly dependent on monocyte CCR2 but not CCR5 chemokine receptor 
expression. Moreover, using CCR2-deficient mice and function blocking anti-
CCR2 antibodies in an IV pneumonia model, it was demonstrated that alveolar 
macrophage accumulation was solely dependent on monocyte-expressed 
CCR2 in vivo. In addition, the contribution of lung exudate macrophages to 
alveolar leakage formation during lethal IV pneumonia was delineated. Exudate 
macrophage accumulation in the lungs of PR/8 infected wildtype mice was 
associated with increased alveolar epithelial cell apoptosis, lung leakage and 
mortality. All these features of acute lung injury were strongly reduced in CCR2-
/- mice and in wildtype mice treated with function blocking anti-CCR2 antibodies. 
Among several proapoptotic mediators analysed, TNF-related apoptosis-
inducing ligand (TRAIL) gene expression was found to be markedly upregulated 
in alveolar exudate macrophages as compared to peripheral blood monocytes. 
Moreover, among the different alveolar recruited leukocyte subsets, TRAIL 
protein was predominantly expressed on macrophages. Finally, repetitive 
treatment of IV-infected mice with a monoclonal anti-TRAIL antibody resulted in 
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significant reduction of alveolar epithelial cell apoptosis, attenuated alveolar 
leakage and significantly increased survival.  
Collectively, these findings demonstrate a major role of the CCL2/CCR2 axis in 
monocyte transepithelial migration. Additionally, CCR2-dependently recruited 
exudate macrophages were shown to be key players in the induction of alveolar 
leakage and mortality in influenza virus pneumonia, with macrophage TRAIL 
expression-linked epithelial apoptosis being recognized as major underlying 
mechanism and potential treatment target. 
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5. Zusammenfassung 
 
Die Influenza A Viruspneumonie verläuft häufig rasch progredient bis hin zum 
akuten Lungenversagen und ist gekennzeichnet durch eine hohe Mortalität. In 
den frühen Stadien der Infektion kommt es zu einer ausgeprägten Rekrutierung 
von Monozyten/Makrophagen, neutrophilen Granulozyten und Lymphozyten ins 
Lungenparenchym. Insbesondere den Makrophagen wird eine bedeutende 
Rolle in der Immunabwehr gegen das Influenzavirus (IV) zugeschrieben. 
Jedoch waren die molekularen Pfade der transepithelialen Rekrutierung 
peripherer Blutmonozyten in den Alveolarraum und die mögliche Rolle dieser 
alveolär akkumulierenden Makrophagen bei der Induktion des pulmonalen 
Epithelschadens mit Verlust der alveolären Barrierefunktion bei der 
Influenzapneumonie bis dato ungeklärt. In der vorgelegten Arbeit wurden die 
der IV-induzierten transepithelialen Monozytenrekrutierung zugrundeliegenden 
Chemokin-Rezeptor-Interaktionen in vitro und in vivo analysiert. Die Infektion 
primärer muriner Alveolarepithelzellen mit dem Maus-adaptierten Influenza A 
Virus PR/8 induzierte eine ausgeprägte Freisetzung der Monozyten-
rekrutierenden Chemokine CCL2 und CCL5 und eine deutliche transepitheliale 
Migration peripherer Blutmonozyten. Diese war strikt abhängig von monozytär 
exprimiertem CCR2, nicht jedoch von CCR5. In einem IV-Pneumonie Modell 
konnte darüber hinaus anhand CCR2-defizienter Mäuse und mittels Applikation 
von anti-CCR2-Antikörpern gezeigt werden, dass die alveoläre 
Makrophagenrekrutierung auch in vivo primär durch monozytär exprimiertes 
CCR2 vermittelt ist. Zusätzlich wurde der Beitrag alveolär rekrutierter 
Makrophagen zum Verlust der alveolären Schrankenfunktion in der IV-
Pneumonie untersucht. Die Akkumulation rekrutierter Makrophagen in der IV-
infizierten Lunge von Wildtyp-Mäusen ging einher mit signifikant vermehrter 
Alveolarepithelzellapoptose, verstärkter alveolärer Leakage und höherer 
Mortalität im Vergleich zu CCR2-defizienten Mäusen oder anti-CCR2-
vorbehandelten Tieren. Die Analyse der Genexpression verschiedener pro-
apoptotischer Faktoren ergab eine signifikante Hochregulation des TNF-related 
apoptosis-inducing ligand (TRAIL) in alveolär rekrutierten Makrophagen im 
Vergleich zu peripheren Blutmonozyten IV-infizierter Tiere, wobei TRAIL 
ausschliesslich auf der Oberfläche alveolärer Makrophagen, nicht jedoch auf 
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anderen alveolären Leukozytensubpopulationen exprimiert war. Schliesslich 
führte die repetitive Applikation eines monoklonalen anti-TRAIL-Antikörpers zu 
einer deutlichen Reduktion der alveolarepithelialen Apoptose, der alveolären 
Schrankenstörung und zum signifikant verbesserten Überleben IV-infizierter 
Tiere. 
In der vorgelegten Arbeit konnte die CCL2/CCR2-Achse als wichtigster 
Signalpfad bei der IV-induzierten transepithelialen Monozyten-
/Makrophagenrekrutierung identifiziert werden. Darüber hinaus konnte gezeigt 
werden, dass CCR2-abhängig alveolär rekrutierte Makrophagen durch die 
Expression des pro-apoptotischen Faktors TRAIL eine Schlüsselrolle in der 
Induktion der alveolarepithelialen Apoptose und des Zusammenbruchs der 
alveolären Schranke übernehmen und dabei wesentlich zur Mortalität bei der 
Influenza Viruspneumonie beitragen. 
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7. Supplement 
 
7.1 Materials and source of supply 
Abbocath Abbott 
AEC staining kit Sigma 
Aequous mounting medium Dako 
Agarose, low-melting Sigma-Aldrich 
Ammoniumchloride solution Merck 
Antibiotics (Pen/Strep) PAA 
a-hamster-Alexa 488 IgG Molecular Probes 
a-human/mouse pro-SPC mAb Chemicon 
anti-influenza nucleoprotein mAb Biodesign 
a-mouse biotinylated CD8α mAb BD Pharmingen 
a-mouse biotinylated I-A/I-E mAb BD Pharmingen 
a-mouse CCL2 mAb R&D systems 
a-mouse CD4-FITC mAb BD Pharmingen 
a-mouse CD4 MACS mAb Miltenyi Biotech 
a-mouse CD8 MACS mAb Miltenyi Biotech 
a-mouse CD11b-FITC mAb BD Pharmingen 
a-mouse CD11c-PE mAb BD Pharmingen 
a-mouse CD11c-PE-Cy5.5 mAb Caltag  
a-mouse CD19 MACS mAb Miltenyi Biotech 
a-mouse CD45.2-FITC mAb BD Pharmingen 
a-mouse CD45.1-PE  mAb BD Pharmingen   
a-mouse CD45.2- PercP-Cy5.5 mAb BD Pharmingen 
a-mouse CD115-PE mAb Serotec 
a-mouse DR5 mAb R&D 
a-mouse F4/80-Alexa647 mAb Caltag 
a-mouse F4/80-Alexa488 mAb Caltag  
a-mouse GR1-FITC mAb BD Pharmingen 
a-mouse GR1-PE mAb BD Pharmingen 
a-mouse GR1-PE-Cy7 mAb  BD Pharmingen 
a-mouse NK1.1-APC mAb BD Pharmingen 
a-mouse T1α/Podoplanin/gp36  Abcam 
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a-mouse TRAIL mAb (LEAF) Biolegend 
a-mouse TRAIL-PE mAb Biolegend  
a-mouse widespread cytokeratin mAb  Dako 
annexin V-Alexa647  Molecular Probes 
a-IV nucleoprotein mAb  Biodesign 
Biotinylated a-mouse CD16/32 mAb  BD Pharmingen 
Biotinylated a-mouse CD45 mAb BD Pharmingen 
Bovine serum albumin (BSA) Sigma 
CaCl2 Roth 
Cell culture plates/transwells BD Biosciences 
Colorimetric sandwich ELISA kits R&D systems 
DDT (Dithiotreitol) Invitrogen 
DeadEnd® Colorimetric TUNEL system  Promega 
dH2O Pharmacia & Upjohn 
Dispase Beckton Dickinson 
DNAse Serva 
DNTPs Roche 
Dulbecco´s modified eagle medium (DMEM) PAA 
EDTA Biochrom 
EDTA tubes Sarstedt 
Fc-Block BD Pharmingen 
Fetal calf serum (FCS) Gibco 
FITC-Albumin Sigma 
Hank´s buffered saline solution (HBSS) PAA 
Hepes buffer Gibco 
HRP-conjugated anti-mouse IgG Santa Cruz Biotechnology 
IgG2b rat isotype control antibody (azide-free) BD Pharmingen 
Isoflurane Abbott 
isotype-PE (rat IgG2aк) Biolegend 
Ketamin hydrochloride (Ketavet®) Pharmacia & Upjohn 
LEAF IgG2a rat isotype control antibody  Biolegend 
Leibovitz L15 medium Gibco 
Lympholyte® Biozol 
MACS columns Miltenyi Biotech 
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Methylcellulose Fluka Biochemika 
MgCl2 Roth 
MMLV-Reverse Transcriptase Invitrogen 
NaCl 0.9% Pharmacia & Upjohn 
NaCl powder Roth 
Pappenheim staining solutions  Merck 
(May-Grünwald/Giemsa) 
PE-conjugated anti-rat IgG  Serotec 
PeqGold Total RNA kit  PeqLab 
PFA (paraformaldehyde) Sigma 
Phosphate-buffered saline (PBS) PAA 
Platinum SYBR® Green qPCR SuperMix  Invitrogen 
Random Hexamers Böhringer Mannheim 
rat IgG isotype antibody BD Pharmingen 
Recombinant murine CCL2 Peprotech 
Recombinant murine CCL5 R&D systems 
RLT buffer/ß-mercaptoethanol Quiagen 
Rnase InhibitoR Promega 
RNeasy Micro Kit  Qiagen 
RPMI 1640 medium PAA 
SA-APC-Cy7 BD Pharmingen 
Saponin Calbiochem 
5x 1st strand buffer Invitrogen 
Streptavidin-linked MagneSphere®  Promega 
Paramagnetic Particles 
SYBR® Green Invitrogen 
Syringes Braun Melsungen 
TissueTek OCT  Sakura 
Transgenic/mutated mice  The Jackson Laboratory 
(CCR2-/-, CCR5-/-, CD45.1)  
Triton X-100 Sigma 
Trypan blue Sigma 
Trypsin PAA 
Tween 20 Sigma 
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Ultra low cluster cell culture plates Costar 
Wildtype mice (BALB/c; C57/BL6) Charles River 
Xylazin hydrochloride (Rompun®) Bayer 
 
 
7.2 Technical equipment and manufacturer 
ABI 7900 Sequence Detection System  Applied Biosystems 
Cell Culture Incubator Hereus 
Centrifuges Heraeus 
Cytocentrifuge Shandon 
Digital Imaging Software Leica 
FACSCanto Becton Dickinson 
FACSDiva Software Package Becton Dickinson 
FACSVantage Becton Dickinson 
Fluorescence Spectrometer FLx800 Bio-Tek Instruments 
Leica DM 2000 Light Microscope Leica 
Microplate Reader Molecular Devices 
PE GeneAmp PCR System 2400 Perkin Elmer 
96-well Plate Autowasher Tecan 
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